Blue®M in Dentistry: A Narrative Review of Human Clinical Evidence and Applications

Blue®M is an oral biomaterial product line based on active oxygen-generating formulations containing sodium perborate, honey-derived glucose oxidase, and lactoferrin, available as an oral gel, mouthwash, and toothpaste. This narrative review summarizes the human clinical evidence by product type and clinical indication, with a study-level risk of bias assessment. A structured search of PubMed/MEDLINE, Embase, CENTRAL, and Google Scholar, completed on 27 September 2026, identified 35 eligible human clinical studies. Risk of bias was formally assessed with the revised Cochrane risk of bias tool for 32 randomized trials, including split-mouth designs, and with ROBINS-I for three non-randomized comparative studies. The oral gel was mainly investigated as an adjunct to scaling and root planing and as a topical treatment for postoperative wounds. Periodontal findings were heterogeneous: probing pocket depth and attachment-level gains were reported in several small split-mouth trials with some concerns or serious risk, whereas no statistically significant between-group benefit was detected in the only trial that was at low risk of bias. Several small studies reported more favorable short-term pain and re-epithelialization outcomes than a conventional periodontal dressing, predominantly at high risk of bias. Mouthwash studies showed no statistically significant between-group differences compared with chlorhexidine, while toothpaste studies showed no consistent superiority over reference products. Overall, the available evidence, weighted by risk of bias, does not demonstrate superiority of Blue®M over established treatments; it may be regarded as a potentially useful adjunct whose comparative clinical value remains uncertain. Adequately powered randomized trials with a blinded outcome assessment, registered protocols, and active comparators are needed.